-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275

Benzinga·08/31/2026 09:55:51
Listen to the news
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.